Extended Data Fig. 1: Characterization of SLCLs.
(a) Proliferation index in SLCLs and LCLs (B95.8), and EBV− BJAB cells measured by CFSE (one-way ANOVA followed by Tukey’s multiple comparison test: (HC SLCL, n = 4; SMS SLCL, n = 6; AMS SLCL n = 5; HC LCL, n = 8 MS LCL, n = 7). (b) Viability of long-term culture of AMS SLCLs compared to HC and SMS SLCLs, LCLs (B95.8), and EBV− BJAB cells (Log-rank Mantel-Cox test). (HC SLCL, n = 4; SMS SLCL, n = 6; AMS SLCL n = 5; HC LCL, n = 8 MS LCL, n = 8). (c) Flow cytometry analysis of EA-D and Zta expression in AMS and SMS and (d) quantitation of flow cytometry using FlowJo software (one-way ANOVA followed by Tukey’s multiple comparison test (HC SLCL, n = 4; SMS SLCL, n = 6; AMS SLCL n = 5; LCL, n = 8). (e) Western blot of EBV latent (EBNA1, EBNA2, LMP1, EBNA3C) and lytic (Zta and Ea-D) genes relative to β-actin in EBV B95.8 strain transformed LCLs (HC LCL n = 4 MS LCL n = 4). (f) RNA-seq summary heatmap showing top EBV lytic genes that are upregulated (red) or downregulated in AMS SLCLs compared to those from HC or SMS SLCLs. (g) RT-qPCR analysis of EBNA1 and LMP1 gene expression in SLCLs compared to LCLs (one-way ANOVA followed by Tukey’s multiple comparison test: (HC SLCL, n = 4; SMS SLCL, n = 6; AMS SLCL n = 5). All data points represent distinct samples tested in triplicate. Data are mean ± SD (DSeq2 Wald Test).
